| Excerpt | Reference |
|---|
| "Gastroesophageal reflux is not synonymous with sliding hiatus hernia." | ( Cohen, S, 1975) |
| "Gastroesophageal reflux disease is commonly encountered by general internists and gastroenterologists." | ( Bloom, BS; Fendrick, AM; Hillman, AL; Schwartz, JS, 1992) |
| "We conclude that gastroesophageal reflux is very common in infants and children and urge the need to evaluate the patients presenting with the symptoms suggesting gastroesophageal reflux by barium esophagram; conservative treatment is the mainstay in the management of these children." | ( Bansal, A; Chana, RS; Singhania, RU, 1989) |
| "Some degree of gastroesophageal reflux is very common in infants and tends to reverse with time." | ( Ferrara, TB; Foker, JE; Johnson, DE; St Cyr, JA; Thompson, TR, 1986) |
| "Gastroesophageal reflux is common in infants and children." | ( Johnson, DG, 1985) |
| "Duodenogastroesophageal reflux is demonstrated using cholescintigraphy in a patient with severe esophagitis." | ( Blue, PW; Ghaed, N; Jackson, JH, 1984) |
| "Gastro-esophageal reflux is discussed with reference to pathogenetic factors and therapy." | ( Güller, R, 1980) |
| "Pediatric gastroesophageal reflux is common and its complications may be serious." | ( Carson, JA; Smith, EI; Tunell, WP, 1980) |
| "We believe gastroesophageal reflux disease is an important factor in the cause of cervical problems." | ( Freeman, J; Goldberg, M; Mendelsohn, M; Rival, R; Rosgen, S; Wong, R, 1995) |
| "Severe gastroesophageal reflux disease is usually a chronic problem with periods of relapse, but effective medical and surgical therapies are available." | ( Marshall, JB, 1995) |
| "(e) Although gastroesophageal reflux is important in the genesis of coffee-sensitivity, there must be other factors which act in concert with reflux to produce symptoms of coffee-sensitivity." | ( Brazer, SR; Dalton, CB; Onken, JE; Schiffman, SS; Smith, JW, 1995) |
| "Gastro-oesophageal reflux is a common phenomenon in infants, and is an aspecific complaint." | ( Vandenplas, Y, 1993) |
| "Although gastroesophageal reflux disease is among the most common disorders seen by gastroenterologists, the wide variation in both its symptoms and severity has led to a lack of consensus about the most appropriate practical approach to treatment of patients with acute symptoms." | ( Reynolds, JC, 1995) |
| "Gastroesophageal reflux is rare in untreated achalasia and esophageal acidity may result from ingestion of acidic foods or production of lactate." | ( Achkar, E; Burke, CA; Falk, GW, 1997) |
| "As GERD is often a chronic condition, we compared the long-term costs of medical and surgical management." | ( Isolauri, J; Nevalainen, J; Viljakka, M, 1997) |
| "Gastroesophageal reflux is part of a generalized foregut motility disorder, which may also include delayed gastric emptying." | ( Brown, RA; Mann, MD; Millar, AJ; Rode, H; Wynchank, S, 1997) |
| "Gastroesophageal reflux is a common condition that in infants may lead to serious complication." | ( Ferreira, C; Jones, AB; Lohoues, MJ; Machida, H; Roy, CC; Scott, RB; Smith, L, 1997) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "The impact of GERD is most striking on measures of pain, mental health, and social function." | ( Maton, PN; Revicki, DA; Sorensen, S; Wood, M, 1998) |
| "Symptomatic gastroesophageal reflux is a common complication of pregnancy and lactation." | ( Armstrong, D; Marshall, JK; Thompson, AB, 1998) |
| "Gastroesophageal reflux is frequently found in patients with chest pain despite normal coronary anatomy, but little data on the effect of specific medication exist." | ( Anggiansah, A; Chambers, J; Cooke, R; Owen, W, 1998) |
| "Gastroesophageal reflux is common in children after successful repair of esophageal atresia (EA), and may be related to a congenital neuronal abnormality of the esophagus." | ( Bishop, AE; Cheng, W; Polak, JM; Spitz, L, 1999) |
| "Gastroesophageal reflux is generally a benign condition, which resolves spontaneously, and which is usually manifested by digestive signs." | ( Attal, P; Bobin, S, 1999) |
| "pylori and GERD is complex, and it is difficult to give definitive guidelines on the management of H." | ( O'Connor, HJ, 1999) |
| "Gastroesophageal reflux disease is an important and increasingly common condition." | ( Everhart, JE; Ruhl, CE, 1999) |
| "Gastroesophageal reflux is a common condition caused mainly by motility disorders of the upper gastrointestinal tract." | ( Zarling, EJ, 1999) |
| "Asthma and gastro-oesophageal reflux are both common medical conditions and often co-exist." | ( Coughlan, JL; Gibson, PG; Henry, RL, 2000) |
| "Gastro-oesophageal reflux is often associated with cough." | ( Benini, L; Bulighin, GM; Cascio, VL; Ederle, A; Ferrari, M; Fiorino, F; Micciolo, R; Olivieri, M; Sembenini, C; Vantini, I; Zuccali, V, 2000) |
| "The etiology of GERD is multi-factorial and is believed to be principally a consequence of altered motility states in the esophagus and stomach." | ( Dajani, EZ, 2000) |
| "Gastroesophageal reflux is a strong risk factor for this disease." | ( Adami, HO; Bergström, R; Lagergren, J; Nyrén, O, 2000) |
| "Gastro-oesophageal reflux is a frequent, aspecific phenomenon in infants and children." | ( Hegar, B; Vandenplas, Y, 2000) |
| "Gastroesophageal reflux is a frequent, nonspecific phenomenon in infants and children." | ( Vandenplas, Y, 2000) |
| "Therapy for gastroesophageal reflux disease is now well established." | ( Sandhu, BK; Sawczenko, A, 1999) |
| "Gastroesophageal reflux disease is the most common esophageal abnormality associated with unexplained chest pain and may be identified by an aggressive trial of anti-reflux therapy or an abnormal prolonged ambulatory pH monitoring study." | ( Katz, PO, 2001) |
| "Gastroesophageal reflux is a common problem in the newborn and preschool periods." | ( Hardy, SM; Heavner, SB; Pillsbury, HC; Prazma, J; White, DR, 2001) |
| "Gastroesophageal reflux is a normal phenomenon recognized in infants as "spitting up." | ( Jones, AB, 2001) |
| "Gastroesophageal reflux is a common, self-limited process in infants that usually resolves by six to 12 months of age." | ( Jung, AD, 2001) |
| "Gastroesophageal reflux disease is a common disorder affecting children worldwide." | ( Abdullah, AM; El Mouzan, MI, 2002) |
| "Gastro-oesophageal reflux is a common clinical disorder associated with a variety of respiratory symptoms, including chronic cough and exacerbation of asthma." | ( Advenier, C; Alt, XE; D'Agostino, B; Daoui, S; Gallelli, L; Rossi, F, 2002) |
| "Pharyngoesophageal gastric acid reflux is thought to initiate chronic posterior laryngitis." | ( Eherer, A; Friedrich, G; Habermann, W; Kiesler, K, 2002) |
| "Gastroesophageal reflux disease is a complex, multifaceted disorder affecting a large proportion of the US population." | ( Frissora, C; Katz, PO, 2002) |
| "Gastroesophageal reflux is a common problem in infancy." | ( Craig, JC; Dalby-Payne, JR; Morris, AM, 2003) |
| "The key feature of GERD is reflux of gastric contents into the esophagus." | ( Haag, S; Holtmann, G, 2003) |
| "Asthma and gastro-oesophageal reflux are both common medical conditions and often co-exist." | ( Coughlan, JL; Gibson, PG; Henry, RL, 2003) |
| "GERD is primarily a motility disorder of the oesophagus, however, there are no available promotility drugs on the market." | ( Thjodleifsson, B, 2004) |
| "Gastroesophageal reflux is implicated in some cases of laryngitis." | ( Brake, HM; Cole, IE; Cook, IJ; Maclean, JC; Szczesniak, MM; Williams, RB, 2004) |
| "GERD is a common condition and acid-suppressing agents are the mainstay of treatment." | ( Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T, 2004) |
| "Treatment of GERD is mainly drug therapy; however, it is believed that providing guidance in changing life-style and providing information about the disease will permit long-lasting relief of the symptoms." | ( Harasawa, S; Nagoshi, A, 2004) |
| "Gastro-oesophageal reflux is a common condition in pregnancy." | ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| "GERD is more common in British compared with South-East Asian dyspeptic patients suggesting that race and/or western lifestyle are important risk factors." | ( Axon, AT; Follows, M; Ford, AC; Goh, KL; Mahadeva, S; Moayyedi, P; Raman, MC, 2005) |
| "Most likely, GERD is one of many triggers provoking BA attacks." | ( Chereĭskaia, NK; Isakov, VA; Ivanova, OV; Paleev, NR, 2005) |
| "In conclusion, GERD is significantly more common in nonatopic children with asthma-like airway disease compared to the controls and clinical improvement is significant after acid suppressor treatment." | ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
| "Although GERD is a disorder of gastrointestinal motility and structure, the most effective therapy is based on the use of acid antisecretory drugs." | ( Armstrong, D, 2005) |
| "GERD is a highly prevalent condition in asthma patients." | ( Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005) |
| "Gastroesophageal reflux disease is related to various laryngeal sequelae." | ( Lee, YW; Park, HT; Roh, JL, 2006) |
| "Laryngopharyngeal or gastroesophageal reflux is associated with laryngeal airway hyperreactivity (LAH), but neither the cause-effect relationship nor the underlying mechanism has been elucidated." | ( Chang, SY; Ho, CY; Kou, YR; Tsai, TL, 2006) |
| "GERD is a chronic disease and its treatment is problematic." | ( Pereira, Rde S, 2006) |
| "Gastroesophageal reflux is related to various laryngeal manifestations." | ( Roh, JL; Yoon, YH, 2006) |
| "Gastroesophageal reflux is common during pregnancy." | ( Ennen, CS; Magann, EF, 2006) |
| "Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux." | ( Goh, KL; Gopala, K; Qua, CS; Wong, CH, 2007) |
| "Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce." | ( Abedi, B; Alimohamadi, SM; Ghotbi, MH; Malekzadeh, R; Mamarabadi, M; Mofid, A; Mostajabi, P; Nasseri-Moghaddam, S; Nouraie, M; Razjouyan, H; Sohrabpour, AA; Sotoudeh, M; Tofangchiha, S, 2007) |
| "Gastroesophageal reflux disease is thought to be the commonest cause of 'non-cardiac chest pain'." | ( Azman, W; Goh, KL; Mohd, H; Qua, CS; Wong, CH, 2009) |
| "Functional gastroesophageal reflux is seen in obese patients, especially with decreased levels of adiponectin." | ( Hibi, T; Hosoda, H; Iida, T; Iwasaki, E; Kangawa, K; Masaoka, T; Nishizawa, T; Sugino, Y; Suzuki, H, 2008) |
| "Extraesophageal reflux is common." | ( Bailey, M; Birchall, MA; Gutowska-Owsiak, D; Inman, CF; Johnston, N; Koufman, JA; Pazmany, L; Phillips, A; Postma, G; Rees, LE; Stokes, CR, 2008) |
| "Patients with gastroesophageal reflux disease are subdivided into non-erosive (NERD) and erosive reflux disease (ERD)." | ( Basting, N; Biesterfeld, S; Galle, PR; Goetz, M; Hoffman, A; Kiesslich, R; Mudter, J; Neurath, MF; Tresch, A, 2009) |
| "ProGERD is a prospective multicentre cohort study of 6215 adult out-patients with GERD." | ( Jaspersen, D; Labenz, J; Leodolter, A; Lind, T; Malfertheiner, P; Nocon, M; Richter, K; Stolte, M; Vieth, M; Willich, SN, 2009) |
| "Gastroesophageal reflux is common among patients with asthma but often causes mild or no symptoms." | ( Anthonisen, NR; Castro, M; Holbrook, JT; Leone, FT; Mastronarde, JG; Teague, WG; Wise, RA, 2009) |
| "Asymptomatic gastroesophageal reflux is not a likely cause of poorly controlled asthma." | ( Anthonisen, NR; Castro, M; Holbrook, JT; Leone, FT; Mastronarde, JG; Teague, WG; Wise, RA, 2009) |
| "Gastroesophageal reflux is a well-recognized complication of obesity." | ( Chang, CG; Perez, E, 2009) |
| "Gastro-oesophageal reflux is frequent in chronic airway diseases and is considered a trigger for symptoms." | ( Advenier, C; Chen, H; Cui, Y; Devillier, P; Kuang, X; Wang, H; Xia, Z; Xu, Z; Zemoura, L; Zhu, L, 2010) |
| "Gastro-oesophageal reflux is the third most frequent cause of chronic cough." | ( Fonseca, G, 2009) |
| "Gastroesophageal reflux disease is a highly prevalent condition that imposes a significant economic impact on the US health care system." | ( Chertoff, J; Fass, R; Lacy, BE; Pandolfino, JE; Richter, JE; Rothstein, RI; Spangler, C; Vaezi, MF; Weiser, K, 2010) |
| "Gastroesophageal reflux is common among patients with postnasal drainage." | ( Allocco, CT; Clement, LE; Duncavage, JA; Goutte, M; Hagaman, DD; Lanza, DC; McCafferty, BA; Slaughter, JC; Sparkman, C; Tanner, SB; Vaezi, MF; Wasden, CM; Wirth, D, 2010) |
| "The prevalence of GERD is believed to be less in Asia than in Western countries." | ( Ahuja, V; Gupta, S; Madan, K; Raizada, A; Sharma, MP; Sharma, PK, 2011) |
| "Gastro-oesophageal reflux is common in preterm newborns; at present, no studies have evaluated the efficacy of sodium alginate in this population." | ( Aceti, A; Capretti, MG; Corvaglia, L; De Giorgi, M; Faldella, G; Mariani, E, 2011) |
| "As gastroesophageal reflux disease is a "disease of the XXI century", the relevance of its diagnosis at early stages is high." | ( Akhunova, DM; Baulin, AA; Baulin, VA; Berezina, NP; Kupriianov, MP; Polosin, AV; Shcherbakov, PL; Starodubtsev, VA, 2010) |
| "Gastroesophageal reflux is frequently associated with sleep-related breathing disorders." | ( Esteller, E; Mearin, F; Modolell, I; Segarra, F, 2011) |
| "Gastroesophageal reflux disease is a highly frequent disorder classically characterized by the presence of heartburn and/or acid regurgitation that improves with drug therapy that reduces acid content in the stomach." | ( Serra Pueyo, J, 2014) |
| "Gastroesophageal reflux is a common disorder closely related to chronic airway diseases, such as chronic cough, asthma, chronic bronchitis, and chronic obstructive disease." | ( Cao, AL; Cheng, YM; Liu, CF; Sun, YS; Wang, HW; Wang, Y; Wu, DZ; Zhang, BB; Zheng, JP; Zhu, SL, 2014) |
| "Gastroesophageal reflux disease is the primary cause of OA, usually managed with acid suppression therapy." | ( Baxter, JN; Davies, C; Griffiths, AP; Haboubi, HN; Jenkins, GJ; McAdam, E; Spencer-Harty, S, 2015) |
| "GERD is a public health concern as its worldwide incidence and associated complications are increasing alongside the exponentially increasing problem of obesity." | ( Bardou, M; Goirand, F; Le Ray, I, 2014) |
| "Aggravation of GERD is considered as one of the triggers of asthma attacks." | ( Popadynets', IR, 2013) |
| "pylori and GERD is still unclear." | ( Chen, MH; Hou, XH; Li, ZS; Lin, SR; Lu, JJ; Meng, LM; Xue, Y; Yan, XE; Zhang, J; Zhou, LY, 2015) |
| "Gastroesophageal reflux is an important pathogenic factor to the VPG." | ( Chen, L; Hong, Y; Li, Z; Shen, W; Xu, H, 2015) |
| "This spectrum of GERD is strongly predominant in males due to an unidentified mechanism." | ( Asanuma, K; Iijima, K; Shimosegawa, T, 2016) |
| "GERD is highly prevalent in southern India." | ( Hergens, MP; Leena, KB; Plymoth, A; Shenoy, KT; Wang, HY; Ye, W; Yin, L, 2016) |
| "Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate." | ( Bonella, F; Costabel, U; Kirchgässler, KU; Kolb, M; Koschel, D; Kreuter, M; Maher, TM; Renzoni, E; Spagnolo, P; Weycker, D; Wuyts, W, 2017) |
| "Gastroesophageal reflux disease is a common disorder in humans and has been treated for the last 67 years using fundoplication." | ( Friedrichs, N; Stelzner, F, 2017) |
| "Although gastroesophageal reflux disease is the main cause of noncardiac chest pain (NCCP), proton pump inhibitors (PPIs) benefit a minority of patients." | ( Christidou, A; Denaxas, K; Galanopoulos, M; Kamberoglou, D; Karamanolis, DG; Karamanolis, G; Katopodi, K; Mantzaris, GJ; Papatheodoridis, G; Tsoukali, E; Varytimiadis, L; Viazis, N, 2017) |
| "LPR and GERD are highly prevalent in patients with Sjögren syndrome." | ( Dos Anjos Corvo, MA; Eckley, CA; Liquidato, B; Rizzo, LV; Sardinha, LR, 2017) |
| "GERD is believed to cause nonesophageal symptoms, such as those provoked by ear, nose, throat, or respiratory disorders." | ( Sifrim, D; Vaezi, MF, 2018) |
| "Gastroesophageal reflux disease is more common in males than in females." | ( Asano, N; Asanuma, K; Hamada, S; Iijima, K; Imatani, A; Koike, T; Masamune, A; Mikami, T; Shimosegawa, T; Torihata, Y, 2018) |
| "Gastroesophageal reflux disease is very common in industrialized countries and rapidly and significantly increasing even in developing countries." | ( Calogero, A; Gallo, M; Langella, C; Marino, M; Naviglio, D, 2018) |
| "Gastroesophageal reflux disease is widely reported most prevalent disease of the gastrointestinal tract." | ( Ahmed, F; Akhter, A; Alam, MS; Banik, RK; Chowdhury, M; Haque, A; Saha, SK; Saifullah, AM; Shil, BC, 2018) |
| "The prevalence of GERD is currently estimated to be 8-33% with the incidence of disease only expected to increase over time." | ( Bilal, M; Chatila, AT; Krill, T; Nguyen, MTT; Reep, G; Roark, R, 2020) |
| "Gastroesophageal reflux disease is commonly associated with sleeve resections and warrants postoperative acid reducing therapy." | ( Chau, WY; Dobruskin, L; Sharma, N, 2019) |
| "Gastroesophageal reflux is a common gastrointestinal issue that can lead to aspiration and contribute to respiratory problems." | ( Kaakoush, NO; Krishnan, U; Leach, ST; Singh, H; Tedla, N, 2020) |
| "Gastroesophageal reflux is a normal physiologic process occurring several times a day in healthy infants." | ( Gokce, S; Koc, FU; Turk, S, 2022) |
| "The diagnosis of GERD is based on the GERD-HRQL questionnaire and upper endoscopy." | ( Al Dossari, HM; Aldawsari, MA; Aldossary, H; Attia, M; El Nakeeb, A; El Sorogy, M; Elrefai, M; Kayed, T; Mohammed, MM; Sewefy, AM; Zaid, A, 2022) |
| "Gastroesophageal reflux disease is a common condition worldwide." | ( Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A, 2023) |
| Excerpt | Reference |
|---|
| "Conventional medical treatment for gastroesophageal reflux disease involves life-style modifications and combination drug therapy, but few studies have included these features in their protocols." | ( Spechler, SJ, 1992) |
| "In men with complicated gastroesophageal reflux disease, surgery is significantly more effective than medical therapy in improving the symptoms and endoscopic signs of esophagitis for up to two years, although medical treatment is also effective." | ( Spechler, SJ, 1992) |
| "The presence of duodenoesophageal reflux increased the frequency and changed the histologic type of esophageal cancer in nitrosamine-treated rats." | ( Attwood, SE; DeMeester, TR; Hinder, RA; Mirvish, SS; Smyrk, TC; Stein, HJ, 1992) |
| "Fifteen children with gastro-esophageal reflux took part in a treatment trial with a regimen of magnesium hydroxide and aluminium hydroxide for 8 weeks period (700 mmol/1." | ( Balsamo, V; Carroccio, A; Cavataio, F; Iacono, G; Ippolito, S; Kazmierska, I; Montalto, G, 1991) |
| "We conclude that gastroesophageal reflux can play a significant role in some patients with nonallergic pulmonary disease and that its treatment can improve pulmonary symptoms and objective measurements of pulmonary function." | ( Carrasco, E; Galleguillos, F; Larrain, A; Pope, CE; Sepulveda, R, 1991) |
| "In order to investigate the response of gastroesophageal reflux after medically induced healing of esophagitis and its relation to the occurrence of relapse during prophylactic treatment, 20 patients with erosive/ulcerative esophagitis underwent 24 hour esophageal pH monitoring before and after healing achieved with 12 to 24 weeks with ranitidine 150 or 300 mg bd." | ( Bianchi Porro, G; Pace, F; Sangaletti, O; Zhu, H, 1991) |
| "Cisapride was used to treat gastro-oesophageal reflux in seven children with neurodevelopmental disorders and in 15 children who were neurologically normal." | ( Brueton, MJ; Clarke, GS; Sandhu, BK, 1990) |
| "Gastroesophageal reflux (GER) may contribute to the persistence of asthma and may be triggered and/or exacerbated by treatment with bronchodilatory and cortisone drugs." | ( Barberio, G; Di Pasquale, F; Morabito, L; Pajno, GB; Pollicino, A; Ruggeri, C; Terranova, ML, 1989) |
| "Although gastroesophageal reflux disease in infancy has a naturally self-limited course with conservative care (thickened feedings and posture adjustment), extensive pharmacologic therapy is needed in the presence of esophagitis." | ( Amarri, S; Astolfi, R; Balli, F; Conti-Nibali, S; Cucchiara, S; Gobio-Casali, L; Guandalini, S; Magazzú, G; Staiano, A, 1989) |
| "The patients with gastroesophageal reflux were put on medical treatment." | ( Bansal, A; Chana, RS; Singhania, RU, 1989) |
| "Gastroesophageal reflux (GER) disease is a common, multifactorial medical condition that may be difficult to treat." | ( Richter, JE, 1986) |
| "As telenzepine reduces gastroesophageal reflux time during and after meals and in supine position it may be tried as adjuvant treatment in esophageal reflux disease." | ( Armbrecht, U; Reul, W; Stockbrügger, RW, 1988) |
| "We conclude that, in patients with gastroesophageal reflux disease, ranitidine therapy, 150 mg twice daily, markedly reduced the heartburn symptoms of reflux disease and significantly improved the endoscopic appearance of the esophageal mucosa." | ( Barwick, KW; McCallum, RW; Nardi, R; Robinson, M; Sontag, S, 1987) |
| "Medical treatment of gastroesophageal reflux disease often results in improvement of symptoms." | ( Lieberman, DA, 1988) |
| "It has been suggested that gastroesophageal reflux scintigraphy (GRS) might be useful in assisting one in determining therapy for patients suspected of aspirating or becoming apneic secondary to gastroesophageal reflux." | ( Adams, JC; Fawcett, HD; Hayden, CK; Swischuk, LE, 1988) |
| "Gastro-esophageal reflux is discussed with reference to pathogenetic factors and therapy." | ( Güller, R, 1980) |
| "When 146 of the 228 patients with gastroesophageal reflux disease were given enough ranitidine (mean, 630 mg/d; range, 300-3000 mg/d) for the relief of all pyrosis symptoms and healing of all esophageal mucosal disease, there were no significant differences in ranitidine therapy between each decade." | ( Abdulian, JD; Chen, YK; Collen, MJ, 1995) |
| "A 43-year-old woman with gastroesophageal reflux disease developed a dystonic-like reaction approximately 3 days after starting oral cisapride therapy." | ( Abercrombie, SA; Bucci, KK; Haverstick, DE, 1995) |
| "Gastroesophageal reflux disease (GERD) is a common disorder which may result in esophageal ulcers, erosions, strictures and motility disorders if it is not treated promptly." | ( Kaplan, B; Koppelo, KL, 1994) |
| "Treatment of gastro-oesophageal reflux with omeprazole in patients with nocturnal asthma and gastro-oesophageal reflux does not improve asthma symptoms or peak expiratory flow rate." | ( Butland, RJ; Ford, GA; Oliver, PS; Prior, JS; Wilkinson, SP, 1994) |
| "The phases of therapy for gastroesophageal reflux disease (GERD) and the efficacy, safety, and cost of the various drugs used are discussed." | ( Garnett, WR, 1993) |
| "Gastroesophageal reflux disease (GERD) is multifactorial disorder in which acid exposure has a central role in the mucosal damage, and the mainstay of medical treatment is the suppression of gastric acid secretion justifying the use of H2 receptors antagonists." | ( Konturek, SJ; Lorens, K; Maj, A; M[aczka, M; Sito, E; Thor, PJ, 1993) |
| "One hundred forty-six patients with gastroesophageal reflux disease were treated with ranitidine in doses that resulted in complete healing of esophagitis and disappearance of pyrosis." | ( Collen, MJ; Johnson, DA; Sheridan, MJ, 1994) |
| "A gastroesophageal reflux was diagnosed during the first weeks of life in a girl; she was not treated." | ( Beydon, N; Bourrillon, A; Faure, C; Mayer, M, 1993) |
| "Although gastroesophageal reflux disease is among the most common disorders seen by gastroenterologists, the wide variation in both its symptoms and severity has led to a lack of consensus about the most appropriate practical approach to treatment of patients with acute symptoms." | ( Reynolds, JC, 1995) |
| "A 2-month-old infant with gastroesophageal reflux was treated with cisapride." | ( Bryant, RM; Fenrich, AL; Grifka, RG; Lewin, MB, 1996) |
| "To review gastroesophageal reflux disease (GERD) and its treatment, with emphasis on the use and place of omeprazole, a proton pump inhibitor." | ( Hara, DS; Joe, RH; Skoutakis, VA, 1995) |
| "Medical treatment of duodenogastroesophageal reflux in postgastrectomy patients has been disappointing." | ( Richter, JE; Sears, R; Vaezi, MF, 1996) |
| "A total of 3409 patients with gastro-oesophageal reflux disease were treated with roxatidine acetate." | ( Botzler, R; Friedrich, P; Kriech, W; Mayershofer, R, 1996) |
| "Documenting abnormal gastroesophageal reflux helps direct appropriate therapy, and proximal pH monitoring may identify patients with pulmonary symptoms who respond to anti-reflux therapy." | ( Castell, DO; Castell, JA; Schnatz, PF, 1996) |
| "In patients with severe gastro-oesophageal reflux disease both cisapride and ranitidine demonstrably lower oesophageal acid exposure, but neither therapy predictably normalizes it." | ( Kahrilas, PJ; Pouderoux, P, 1995) |
| "Although gastroesophageal reflux disease (GERD) is believed to be primarily a motor disorder, current medical therapy is based on the inhibition of acid secretion, since it is the deleterious effects of the acidic refluxate that lead to the symptoms and complications of GERD." | ( Richter, JE, 1997) |
| "Gastroesophageal reflux is rare in untreated achalasia and esophageal acidity may result from ingestion of acidic foods or production of lactate." | ( Achkar, E; Burke, CA; Falk, GW, 1997) |
| "Gastro-oesophageal reflux disease may be treated with a drug forming a floating neutral raft in the stomach." | ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
| "Gastro-oesophageal reflux disease (GERD) can be effectively treated pharmacologically or surgically." | ( Isolauri, J; Nevalainen, J; Viljakka, M, 1997) |
| "In Finland, antireflux surgery for GERD is cheaper than lifetime treatment with proton pump inhibitors." | ( Isolauri, J; Nevalainen, J; Viljakka, M, 1997) |
| "Successful treatment of gastro-oesophageal reflux disease (GORD) has traditionally been assessed as healing of reflux oesophagitis, which may not be relevant in patients with moderate disease." | ( Carling, L; Hatlebakk, JG; Johnsson, F; Thøgersen, T; Vilien, M; Wetterhus, S, 1997) |
| "pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| "A total of 26 GERD patients were studied during omeprazole maintenance therapy." | ( Biemond, I; Bloemena, E; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Lamers, CB; Meuwissen, SG; Nelis, GF; Schenk, BE, 1998) |
| "in resolving heartburn in GERD patients who remained symptomatic after 6 wk of therapy with ranitidine 150 mg b." | ( Fennerty, MB; Joelsson, B; Kahrilas, PJ, 1999) |
| "In the first phase, GERD patients with heartburn on > or = 4 of the 7 days before entry were treated with open-label ranitidine 150 mg b." | ( Fennerty, MB; Joelsson, B; Kahrilas, PJ, 1999) |
| "pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study." | ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999) |
| "Medical therapy fails to control gastroesophageal reflux as it does not inhibit regurgitation." | ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999) |
| "Treatment of gastroesophageal reflux disease (GERD) with modern acid-suppressive agents is supposed to be effective and safe." | ( Rantanen, TK; Salo, JA, 1999) |
| "The mortality in conservatively treated GERD has not decreased." | ( Rantanen, TK; Salo, JA, 1999) |
| "A total of 172 symptomatic GERD patients completed a 57-item questionnaire (containing the SF-12; symptom frequency/bothersomeness; problems related to activities, sleep, work disability; overall HRQoL; and treatment satisfaction) at baseline, week 1 [retest (N = 25)], and week 4 [follow-up (N = 100)]." | ( Colwell, HH; Henning, JM; Hunt, RH; Mathias, SD; Pasta, DJ, 1999) |
| "In the treatment of pediatric gastro-oesophageal reflux with cisapride the major recommendations include not to exceed the maximum dose of 0." | ( Hoekstra, JH; Kneepkens, CM; Vandenplas, Y, 1999) |
| "Gastroesophageal reflux (GER) occurs in 2 distinct forms that differ in pathophysiology, clinical presentation, natural history, and therapy: mild GER (with no or minimal esophagitis) and classic, severe reflux (at risk for erosive esophagitis)." | ( Fass, R; Soll, AH, 1999) |
| "Although relatively rare, GERD patients refractory to medical therapy remain a challenge for the clinician." | ( Castell, DO; Hatlebakk, JG; Katz, PO, 1999) |
| "A total of 65 patients with gastroesophageal reflux disease were administered either 40 or 20 mg of p." | ( Lew, E; Martin, P; Maton, PN; Metz, DC; Paul, J; Pisegna, JR; Pratha, V, 2000) |
| "Depending on the severity of the GERD manifestation, pharmacotherapy is often added." | ( Orenstein, SR, 2000) |
| "In asthmatic subjects with gastro-oesophageal reflux, (but who were not recruited specifically on the basis of reflux-associated respiratory symptoms), there was no overall improvement in asthma following treatment for gastro-oesophageal reflux." | ( Coughlan, JL; Gibson, PG; Henry, RL, 2000) |
| "Acid-related diseases such as gastro-oesophageal reflux disease (GORD) and peptic ulcer are a common cause of morbidity and if inadequately treated can lead to serious complications." | ( Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C, 2000) |
| "Forty consecutive GERD patients with impaired esophageal peristalsis entered the study and were randomized in two groups: group 1 with and group 2 without postoperative treatment with cisapride (6 months, 20 mg twice daily)." | ( Gadenstätter, M; Klocker, J; Weiss, H; Wetscher, GJ, 2000) |
| "A total of 318 gastroesophageal reflux patients whose erosive esophagitis was healed in a comparative study of esomeprazole 40 mg, 20 mg, or omeprazole 20 mg, were randomized to maintenance therapy with once daily esomeprazole 40 mg, 20 mg, or 10 mg, or placebo in a U." | ( Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J, 2001) |
| "Most patients with gastro-oesophageal reflux disease (GERD), regardless of endoscopic status, suffer symptomatic relapse within 6 months of stopping acid suppressant therapy." | ( Bang, C; Delle, M; Junghard, O; Lauritsen, K; Lind, T; Moum, B; Omland, TM; Schulz, T; Talley, NJ; Tunturi-Hihnala, H, 2001) |
| "Gastroesophageal reflux disease is the most common esophageal abnormality associated with unexplained chest pain and may be identified by an aggressive trial of anti-reflux therapy or an abnormal prolonged ambulatory pH monitoring study." | ( Katz, PO, 2001) |
| "It is concluded that severe distal oesophageal reflux and obesity predict amelioration in asthma symptoms after 8-week omeprazole treatment in asthmatics with GER." | ( Helenius, H; Hietanen, E; Kiljander, T; Liippo, K; Salomaa, ER; Terho, EO, 2001) |
| "Many patients with gastro-oesophageal reflux disease (GORD) experience chronic relapses and require maintenance therapy for symptomatic relief." | ( Tytgat, GN, 2001) |
| "Maximal treatment of gastroesophageal reflux and nitrazepam 0." | ( Camfield, PR; Dooley, JM; Gordon, KE; Stewart, WA; Wood, EP, 2001) |
| "To evaluate the relationship between gastroesophageal reflux (GER) and obstructive sleep apnea (OSA) and the effect of combined therapy with cisapride and omeprazole." | ( Huang, X; Ke, M; Wang, Z; Xiao, G, 1999) |
| "Key search terms included gastroesophageal reflux, benzimidazoles; omeprazole; lansoprazole; pantoprazole; rabeprazole; receptor antagonists, histamine(2); therapy, combination drug; therapy, combined modality; and combinations, drug." | ( Cross, LB; Justice, LN, 2002) |
| "No studies in patients with GERD demonstrate that the addition of histamine(2) receptor antagonists to twice-daily PPI therapy provides any further benefit above that derived from PPIs alone." | ( Cross, LB; Justice, LN, 2002) |
| "High frequency of gastroesophageal reflux and its consequences among children with cystic fibrosis, as well as the possibility of well-tolerated and efficient treatment of GER, indicate that diagnostics of GER among children with CF should be obligatory." | ( Brodzicki, J; Korzon, M; Trawińska-Bartnicka, M, 2002) |
| "Proton pump inhibitors are used to treat gastroesophageal reflux, a symptom common in pregnancy." | ( Abdollahi, M; Koren, G; Magee, LA; Moretti, ME; Nikfar, S, 2002) |
| "Patients with moderately severe GERD completed the GSAS and SF-36 at baseline and four weeks following treatment." | ( Adler, E; Bhattacharyja, A; Damiano, A; Handley, K; Siddique, R, 2002) |
| "Some patients with gastro-oesophageal reflux disease continue to experience symptoms despite therapy with proton pump inhibitors." | ( Murray, JA; Nzeako, UC, 2002) |
| "Most patients with cough and gastroesophageal reflux disease (GERD) improve on medical treatment with proton pump inhibitors (PPI)." | ( Allen, CJ; Anvari, M, 2002) |
| "Regression analysis was performed on GERD-related costs using treatment patterns, type of PPI drug, and compliance as independent variables of interest." | ( Dodd, S; Durkin, M; Hall, J; Sloan, S, 2002) |
| "In NCCP patients with GERD, as defined by positive results on a 24-hour pH test or presence of esophagitis on endoscopy, omeprazole treatment led to a response in 95% of patients, whereas 90% of GERD-positive patients treated with placebo did not respond." | ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "To investigate the prevalence of gastroesophageal reflux disease (GERD) among patients with bronchial asthma (BA) and to determine the effects of omeprazole therapy on the outcome of asthma in patients with GERD." | ( Agapova, NR; Busarova, GA; Maev, IV; Samsonov, AA, 2002) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | ( O'Morain, CA; Qasim, A, 2002) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "Cure rates for GERD depended significantly on the CYP2C19 genotype status, as well as the grade of GERD before treatment." | ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole." | ( Bhattacharjya, A; Damiano, AM; Johanson, JF; Jokubaitis, L; Murthy, A; Siddique, R, 2002) |
| "Gastro-oesophageal reflux disease has a chronic course, and often requires long-term treatment." | ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "In subjects with gastro-oesophageal reflux disease treated with a gastric antisecretory agent, the extent to which gastric acidity needs to be reduced to prevent pathological oesophageal acid exposure is not known." | ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "In 27 of the subjects with gastro-oesophageal reflux disease, pH was also recorded on days 1, 2 and 8 of treatment with 20 mg omeprazole and 20 mg rabeprazole in a randomized, two-way, cross-over fashion." | ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "In subjects with gastro-oesophageal reflux disease treated with a proton pump inhibitor, the value of the integrated gastric acidity can predict the likelihood of pathological oesophageal reflux." | ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "The Carlsson-Dent gastro-oesophageal reflux disease questionnaire was developed to justify the selection of primary care patients for empirical proton pump inhibitor treatment." | ( de Wit, NJ; Numans, ME, 2003) |
| "Although the diagnosis of gastroesophageal reflux disease (GERD) is based primarily on symptoms experienced by a patient, relatively little attention has been paid to the development and validation of self-administered questionnaires specific to GERD symptoms." | ( Armstrong, D; Goeree, R; Meyer, F; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "Treatment of gastroesophageal reflux (GER) with proton-pump inhibitors (PPI) improves symptoms of asthma in some patients." | ( Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H, 2003) |
| "It has been shown that GERD has a significant impact on patients' quality of life; therefore, improvement of quality of life is one of the major goals of GERD treatment." | ( Kamolz, T; Pointner, R; Velanovich, V, 2003) |
| "In asthmatic subjects with gastro-oesophageal reflux, (but who were not recruited specifically on the basis of reflux-associated respiratory symptoms), there was no overall improvement in asthma following treatment for gastro-oesophageal reflux." | ( Coughlan, JL; Gibson, PG; Henry, RL, 2003) |
| "In gastro-oesophageal reflux disease (GERD) subjects treated with a gastric anti-secretory agent, it is not known whether there is a relationship between heartburn severity and oesophageal acid exposure." | ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "Medical treatment of GERD with PPIs has been demonstrated to equal the success of antireflux surgery in short- and long-term follow-up with reasonably few side effects." | ( Richter, JE, 2003) |
| "A subset of patients with gastro-oesophageal reflux disease (GORD) with refractory symptoms during therapy with proton pump inhibitors (PPIs), have persistent non-acid duodeno-gastro-oesophageal reflux (duodenal reflux)." | ( Janssens, J; Koek, GH; Lerut, T; Sifrim, D; Tack, J, 2003) |
| "Management costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy." | ( Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L, 2003) |
| "To determine the impact of gastro-oesophageal reflux disease (GERD) on the quality of life, to assess changes in the quality of life during treatment with esomeprazole and to define factors that can predict these changes." | ( Jaspersen, D; Kulig, M; Labenz, J; Leodolter, A; Lind, T; Malfertheiner, P; Meyer-Sabellek, W; Schulte, E; Stolte, M; Vieth, M; Willich, SN, 2003) |
| "101 patients with BA and associated GERD being under study were divided into three groups depending on the way of application of the anti-reflux therapy." | ( Balashova, NN; Maev, IV; Shchekina, MI; Viuchnova, ES, 2003) |
| "37 patients suffering from GERD underwent monotherapy with inhibitors of the proton pump: 17 patients were taking Omeprazole 40 mg a day, and 20 patients--Rabeprazole 20 mg a day." | ( Danilin, MS; Kucheriavyĭ, IuA; Maev, IV, 2003) |
| "Before treatment, GERD patients and controls displayed similar dominant frequency, whereas the former had higher dominant power compared with controls, either in fasting (29." | ( Chang, FY; Chen, CY; Jiun, KL; Lee, SD; Lu, CL; Luo, JC; Wu, HC, 2003) |
| "The choice of a medical therapy to treat gastroesophageal reflux disease (GERD) centers around several factors, including the efficacy and safety of the agent and the severity of the patient's symptoms and complications." | ( Maton, PN, 2003) |
| "Radical treatment of GERD allows the pulmonologist to perform correct respiratory treatment and to prevent the development chronic and life-threatening complications." | ( Castagnetti, M; Gentilino, V; Jasonni, V; Martino, F; Mattioli, G; Montobbio, G; Pini Prato, A; Sacco, O, 2004) |
| "Sixty-three GERD patients were randomly divided into the treated group (n = 30) and the control group (n = 33)." | ( Ghen, JY; Pan, F; Qiu, JR, 2004) |
| "Gastroesophageal reflux disease (GERD) is difficult to control with medical therapy in neurologically impaired children." | ( Hirayama, S; Ida, S; Kawahara, H; Kawai, M; Yoshimura, N, 2004) |
| "In nine endoscopy-negative GERD patients, the IL-8 mRNA expression levels were measured before and 8 wk after treatment with lansoprazole." | ( Akazawa, Y; Inoue, K; Isomoto, H; Kanazawa, Y; Kohno, S; Miyazaki, M; Mizuta, Y; Murata, I; Nishi, Y; Ohtsuru, A; Omagari, K; Saenko, VA; Takeshima, F; Yamashita, S, 2004) |
| "Effective therapy for gastro-oesophageal reflux disease (GERD) is associated with improvement in health-related quality of life." | ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Okajima, T; Yamazaki, Y, 2004) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| "Initial therapy of GERD should be started with a full dose of PPI." | ( Hoshino, E; Ishiyama, A; Tsuchida, T, 2004) |
| "Endoscopy-negative gastro-oesophageal reflux disease patients who achieved complete resolution of heartburn after short-term (2-4 weeks) treatment with esomeprazole 20 mg (n = 774) were randomized to receive either esomeprazole 20 mg on-demand (n =311) or lansoprazole 15 mg continuous daily treatment (n = 311) for 6 months." | ( Anderson, M; Chapman, R; Duggan, S; McKeith, D; Rosen, JP; Shepherd, A; Tsai, HH; Vearer, D, 2004) |
| "Adult GERD patients (n = 217) completed demography, symptom, HRQL, and treatment satisfaction questionnaires at baseline and/or after treatment with esomeprazole 40 mg once daily for 4 weeks." | ( Armstrong, D; Austin, P; Barkun, AN; Chiba, N; Degl' Innocenti, A; El-Dika, S; Fallone, CA; Guyatt, GH; Heels-Ansdell, D; Schünemann, HJ; Tanser, L; van Zanten, SV; Wiklund, I, 2005) |
| "The diagnosis and treatment of gastro-oesophageal reflux disease (GERD) presents many problems, despite the fact that significant advances have been made in recent years in the understanding of its pathogenesis and symptomatology." | ( Beglinger, C; Lehmann, FS, 2005) |
| "We present a patient with non-erosive GERD and treatment failure to omeprazole and proven resistance to esomeprazole which, to our knowledge, has only been reported in patients with Barrett's esophagus." | ( Ortiz, V; Ponce, J; Velasco, MJ, 2005) |
| "Gastroesophageal reflux disease (GERD), which is reflux that produces damage or troubling symptoms, afflicts approximately 7% of infants and children to the extent that administration of physician-directed pharmacotherapy is warranted." | ( Gremse, DA; Kling, DF; Orenstein, SR; Pantaleon, CD; Rotenberg, KS, 2005) |
| "One option for patients with symptoms of gastroesophageal reflux disease (GERD) is treatment with proton pump inhibitors without prior endoscopy." | ( Bergheim, R; Fagertun, H; Lund, H; Moum, B; Norman Hansen, A, 2005) |
| "Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks." | ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "The subjects were 33 gastro-oesophageal reflux disease patients, who had already been treated with a full dose of H2 receptor antagonist." | ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "Current therapies to treat gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and other acid-related diseases either prevent stimulation of the parietal cell (H2 receptor antagonists, H2RAs) or inhibit gastric H+,K+-ATPase (e." | ( Andersson, K; Carlsson, E, 2005) |
| "Erosive gastro-oesophageal reflux disease (GERD) is a chronic condition requiring long-term maintenance treatment." | ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| "Adult gastro-oesophageal reflux disease patients received, at enrolment, an acute treatment of esomeprazole 40 mg/day for 4 weeks and, if successfully treated, were randomized into two maintenance treatment strategies: esomeprazole 20 mg/day or esomeprazole on demand for 6 months." | ( Negrini, C; Pace, F; Rossi, C; Savarino, V; Wiklund, I, 2005) |
| "Gastro-oesophageal reflux disease can significantly impair health-related quality of life and esomeprazole therapy allows immediate relief in the acute phase of the disease." | ( Negrini, C; Pace, F; Rossi, C; Savarino, V; Wiklund, I, 2005) |
| "Patients fulfilling the GERD criteria received a 7-day therapy with omeprazole 20 mg bid." | ( Bachórzewska-Gajewska, H; Baniukiewicz, A; Dabrowski, A; Dobrzycki, S; Kamiński, KA; Korecki, J; Musial, WJ; Prokopczuk, P, 2005) |
| "The therapy of gastroesophageal reflux disease (GERD) is uncomplicated in most cases." | ( Bajbouj, M; Meining, A; Schmid, RM; Stein, HJ, 2005) |
| "Gastro-oesophageal reflux disease (GORD) is a recurring condition with many patients requiring long-term maintenance therapy." | ( Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005) |
| "The Gastroesophageal Reflux Disease (GERD) Treatment Satisfaction Questionnaire (GTSQ) was developed to assess satisfaction with GERD medication." | ( Dodd, SL; Flood, E; Howell, J; Shikiar, R; Siddique, R, 2005) |
| "Two hundred five patients with GERD (Los Angeles classification grade A or B) were included in a case-control study according to endoscopic outcome (healed versus unhealed group, matched for confounders) after treatment with 40 mg esomeprazole daily for 4 weeks." | ( Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G, 2005) |
| "Over the whole treatment period, in GERD+/NOC+ subjects (n = 350), esomeprazole provided an 8." | ( Beckman, O; Ekelund, J; Field, SK; Harding, SM; Illueca, M; Kiljander, TO; Nelson, HS; Sostek, MB; Stein, MR, 2006) |
| "To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms." | ( Areni, A; Calabrese, C; Di Febo, G; Fabbri, A; Scialpi, C; Zahlane, D, 2005) |
| "We included 215 patients with gastro-oesophageal reflux disease after starting treatment for 4 weeks with 40 mg esomeprazole once daily." | ( Armstrong, D; Austin, P; Barkun, AN; Chiba, N; Degl'Innocenti, A; El-Dika, S; Fallone, CA; Guyatt, GH; Heels-Ansdell, D; Puhan, MA; Schünemann, HJ; Tanser, L; Veldhuyzen van Zanten, SJ; Wiklund, I, 2006) |
| "Gastroesophageal reflux disease (GERD) is present in up to 75% of patients with chronic refractory ear, nose, and throat (ENT) symptoms, and proton pump inhibitor (PPI) therapy induces symptom relief in the majority of these patients." | ( Feenstra, L; Poelmans, J; Tack, J, 2006) |
| "To determine the prevalence of GERD and response to proton pump inhibitor therapy in patients with difficult-to-control asthma." | ( Chua, CJ; Goh, KL; Liam, CK; Wong, CH, 2006) |
| "Omeprazole treats gastro-oesophageal reflux disease (GORD) by inhibition of acid secretion whereas alginate based reflux suppressants work by forming a low density raft of near neutral pH which floats on the stomach contents and physically impedes gastro-oesophageal reflux." | ( Baxter, T; Choubey, S; Dettmar, PW; Hampson, FC; Jain, A; Little, SL, 2006) |
| "Children with symptoms suggesting GERD underwent prolonged 24h intraesophageal pH monitoring and/or upper GI endoscopy with biopsies before and after a 6 months of pharmaceutical (omeprazole) and nutritional (20% increment of daily caloric intake) treatments." | ( Campanozzi, A; Capano, G; Del Giudice, E; Miele, E; Militerni, R; Romano, A; Scuccimarra, G; Staiano, A; Strisciuglio, C, 2007) |
| "Ten male patients with GERD symptoms and abnormal gastroesophageal reflux were investigated by pH monitoring on days 1 and 15 of continuous oral famotidine administration at 20 mg twice daily, and H." | ( Adachi, K; Azumi, T; Fujisawa, T; Furuta, K; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miki, M, 2006) |
| "Thirty one patients with gastroesophageal reflux disease were treated with a daily oral dose of 20 mg OMP for 28 days." | ( Choi, SK; Joo, YE; Kim, HS; Kim, SJ; Lee, WS; Park, CH; Rew, JS; Sohn, YH, 2006) |
| "Healing and relief from GERD-related symptoms were assessed at first and final visit (after 4 or 8 weeks of treatment)." | ( Begić, I; Bozić, D; Gmajnić, R; Jurcić, D; Khaznadar, E; Kondza, G; Mićunović, N; Ostojić, R; Soldo, I; Vcev, A, 2006) |
| "Pharmacological treatment of GERD with symptoms or with esophageal injury is based on the suppression of acid secretion, particularly with proton pump inhibitors." | ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "Management of the infant with gastroesophageal reflux disease, in addition to nonpharmacological interventions pharmacologic therapy, including metoclopramide HCl and Fe (6 mg/kg per day, oral) was useful for the patients, and their paroxysmal attacks decreased dramatically (0-2 attacks/day)." | ( Kabakuş, N; Kurt, A, 2006) |
| "To assess the GERD symptomatology, the patients completed the ReQuest daily, and analysis was done prior to (7 days), during (28 days), and after treatment (7 days)." | ( Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B, 2006) |
| "To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and response to proton-pump inhibitor therapy." | ( Goh, KL; Gopala, K; Qua, CS; Wong, CH, 2007) |
| "Investigators scored gastro-oesophageal reflux disease symptoms on a 4-point scale [none to severe (0-3)] before and 4 weeks after treatment." | ( Ginsberg, GG; Hoyle, PE; Katz, PO; Monyak, JT; Silberg, DG; Sostek, MB, 2007) |
| "One hundred and sixteen patients of GERD were randomly assigned to two groups, group A treated with Western medicine and group B with integrated Chinese and Western medicine." | ( Bo, P; Xu, HR; Yuan, Y, 2007) |
| "Gastroesophageal reflux disease (GERD) impairs the patient's quality of life (QOL), but the effect of long-term maintenance therapy in elderly patients is unknown." | ( Haruma, K; Kuwabara, M; Miyamoto, M; Nagano, M; Okamoto, T; Tanaka, M, 2007) |
| "Nineteen patients with GERD, 6 with erosive esophagitis (EE), 7 with NERD with abnormal acid exposure (NERD pH+), and 6 with NERD with normal acid exposure (NERD pH-), were treated with esomeprazole 40 mg daily for two months." | ( Chen, MH; Hu, PJ; Lin, JK; Peng, S; Tao, J; Xiao, YL; Xiong, LS, 2007) |
| "The changes in gastroesophageal reflux disease (GERD)-related symptoms on treatment are variously described, but currently available questionnaires have shortcomings." | ( Armstrong, D; Bardhan, KD; Berghöfer, P; Gatz, G; Mönnikes, H; Stanghellini, V, 2007) |
| "Evaluation of the response of gastroesophageal reflux disease (GERD) symptoms to treatment would be facilitated by a brief, valid, reliable and responsive, self-assessed GERD-sensitive scale." | ( Armstrong, D; Bardhan, KD; Berghöfer, P; Bethke, TD; Mönnikes, H; Stanghellini, V, 2007) |
| "To assess the GERD symptomatology, the patients completed the ReQuest daily, and analysis was done prior to (7 days), during (28 days), and after treatment (7 days)." | ( Abdel-Qader, M; Gatz, G; Glatzel, D; Pfaffenberger, B, 2007) |
| "The outcome of gastro-oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately." | ( Achim, A; Bardhan, KD; Pfaffenberger, B; Riddermann, T, 2007) |
| "We studied spontaneous gastroesophageal reflux (GER)-induced esophageal distension using ultrasound imaging and its role in the genesis of esophageal symptoms before and during esomeprazole therapy." | ( Mittal, RK; Rhee, PL; Tipnis, NA, 2007) |
| "In patients with gastroesophageal reflux disease, baseline symptom/problem severity had little association with the global rating of change, whereas a clear association with change in symptoms/problems and on treatment differences was apparent." | ( Junghard, O; Wiklund, IK, 2007) |
| "Omeprazole is an effective treatment for gastroesophageal reflux in children younger than 2 years." | ( Bishop, J; Furman, M; Thomson, M, 2007) |
| "In the treatment of GERD, efficacy of dexrabeprazole 10 mg is better than rabeprazole 20 mg, with regards to improvement/healing of endoscopic lesions and relief from symptoms of regurgitation." | ( Pai, N; Pai, V, 2007) |
| "Twenty patients with gastroesophageal reflux disease (GERD) with symptoms refractory to conventional proton-pump inhibitor (PPI) therapy or with atypical GERD symptoms were included in the study." | ( Molteni, P; Pace, F; Pallotta, S; Porro, GB; Sangaletti, O, 2007) |
| "Thirty gastro-oesophageal reflux disease patients with grade A oesophagitis (studied before and after 4 weeks of therapy with esomeprazole, 40 mg per day) and 15 patients with reflux-related symptoms demonstrated at wireless pH monitoring (non-erosive reflux disease) were compared to 30 healthy volunteers." | ( Bassotti, G; Battaglia, E; Clerici, C; Grassini, M; Mazzocchi, A; Morelli, A; Navino, M; Niola, P; Verna, C, 2007) |
| "Patients with systemic sclerosis and GERD symptoms (n = 14) were treated with omeprazole 20 mg b." | ( Brühlmann, P; Distler, O; Fox, M; Fried, M; Halim, S; Janiak, P; Menne, D; Schwizer, W; Thumshirn, M, 2007) |
| "The total healthcare costs of GERD are high, especially for maintenance treatment." | ( Cuomo, R; Neri, M; Pace, F; Savarino, V; Tonini, M; Vigneri, S, 2007) |
| "In 20 GERD patients with normal esophageal peristalsis an NF was performed, in 20 patients with impaired esophageal peristalsis a PPF was chosen, and 20 patients received proton-pump inhibitor (PPI) treatment." | ( Bodner, J; Bonatti, H; Gadenstaetter, M; Hugl, B; Wetscher, GJ; Wykypiel, H, 2008) |
| "We test the hypothesis that treatment of gastroesophageal reflux disease (GERD) can improve obstructive sleep apnea-hypopnea syndrome (OSAHS)." | ( Friedman, M; Gurpinar, B; Joseph, NJ; Lin, HC; Schalch, P, 2007) |
| "Patients who tested positive for GERD were treated with esomeprazole magnesium 40 mg once daily for 2 to 12 months." | ( Friedman, M; Gurpinar, B; Joseph, NJ; Lin, HC; Schalch, P, 2007) |
| "Treatment of GERD had a significant impact on the reduction of the apnea-hypopnea index, snoring, and daytime sleepiness." | ( Friedman, M; Gurpinar, B; Joseph, NJ; Lin, HC; Schalch, P, 2007) |
| "A subset of patients with gastro-oesophageal reflux disease (GERD) does not achieve complete symptom resolution with proton pump inhibitor (PPI) therapy." | ( Adlis, SA; Chey, WD; Nojkov, B; Rai, J; Rubenstein, JH; Saad, R; Shaw, MJ; Weinman, B, 2008) |
| "IBS and PD impacted GERD symptoms and QoL before and after PPI therapy." | ( Adlis, SA; Chey, WD; Nojkov, B; Rai, J; Rubenstein, JH; Saad, R; Shaw, MJ; Weinman, B, 2008) |
| "These effects raise the possibility that gastroesophageal reflux may occur after bronchodilator therapy." | ( DesBiens, J; Lacy, BE; Liu, MC; Mathis, C, 2008) |
| "Thirty-two patients with GERD, whose continuous high doses of medical treatment with proton-pump inhibitors produced no or only partial symptom relief, underwent laparoscopic Nissen fundoplication." | ( Antoniou, GA; Antoniou, SA; Dalenbäck, J; Delivorias, P; Kalambakas, A; Makridis, C; Natsiopoulos, I, 2008) |
| "Whether patients with typical gastroesophageal reflux disease (GERD) symptoms and without alarm features should be treated empirically or undergo endoscopy first is a debated issue." | ( Dulbecco, P; Giannini, EG; Savarino, V; Scarlata, P; Vigneri, S; Zentilin, P, 2008) |
| "In patients with GERD, empirical treatment with esomeprazole proved to be cost-effective compared with endoscopy-oriented treatment, and did not negatively affect patient HRQL." | ( Dulbecco, P; Giannini, EG; Savarino, V; Scarlata, P; Vigneri, S; Zentilin, P, 2008) |
| "Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD." | ( Chiba, T; Hongo, M; Kinoshita, Y; Kusano, M; Shirai, N; Yamaguchi, K, 2008) |
| "In patients with gastro-oesophageal reflux disease (GORD), dose escalation or drug switching may be considered in those with symptoms that persist despite standard-dose proton pump inhibitor (PPI) therapy." | ( Backlund, A; Eckerwall, G; Fjellman, M; Lind, T; Röhss, K; Wilder-Smith, C, 2008) |
| "The frequency and severity of GERD-related symptoms were significantly reduced during the active treatment period." | ( Gilger, MA; Illueca, M; Tolia, V; Traxler, B; Vandenplas, Y; Youssef, NN, 2008) |
| "It is not clear in which cases GERD should be suspected or how effective the GERD therapy is in treating the asthma." | ( Doi, S; Kameda, M; Nishikido, T; Takamatu, I; Yoshida, Y, 2008) |
| "Patients with coexistent GERD and OSDB noted significant improvement in daytime sleepiness after treatment with pantoprazole over placebo likely related to a reduction in nocturnal reflux-related arousals." | ( Kushner, J; Steward, DL; Surdulescu, V; Suurna, MV; Welge, J, 2008) |
| "To determine the prevalence of gastroesophageal reflux disease in non-cardiac chest pain and the response of chest pain to proton-pump inhibitor therapy." | ( Azman, W; Goh, KL; Mohd, H; Qua, CS; Wong, CH, 2009) |
| "Pantoprazole has indications in gastroesophageal reflux disease and peptic ulcer disease, along with indications as co-therapy in the eradication of Helicobacter pylori infection and in the control of the acid secretion associated with the Zollinger-Ellison syndrome, as well as in NSAID ulcer prevention." | ( Devault, KR, 2007) |
| "Some patients with gastro-oesophageal reflux disease (GORD) remain symptomatic despite proton pump inhibitor (PPI) treatment." | ( Jones, R; Patrikios, T, 2008) |
| "Although erosive gastro-oesophageal reflux disease (GERD) is a highly prevalent condition, there is no specific, valid, reliable and sensitive questionnaire that allows evaluating treatment-induced changes in health-related quality of life (HRQoL)." | ( Chassany, O; Devault, KR; Doerfler, H; Gebauer, U; Holtmann, G; Malagelada, JR; Schmitt, H, 2009) |
| "On-demand treatment of gastroesophageal reflux disease (GERD) with pharmaceutical products is an established, cost-effective strategy." | ( Farup, PG; Heibert, M; Høeg, V, 2009) |
| "Patients with mild/moderate GERD were randomised to a six weeks' on-demand treatment with PRA or Eso20 in a pragmatic, open, multicentre trial." | ( Farup, PG; Heibert, M; Høeg, V, 2009) |
| "Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI)." | ( Furuta, T; Hishida, A; Ikuma, M; Kimura, M; Kodaira, C; Nishino, M; Shirai, N; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M, 2009) |
| "We enrolled 124 patients with erosive GERD whose esophageal mucosal breaks were endoscopically proven to be cured after treatment with lansoprazole 30 mg/day for 8 weeks." | ( Furuta, T; Hishida, A; Ikuma, M; Kimura, M; Kodaira, C; Nishino, M; Shirai, N; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M, 2009) |
| "We entered the MeSH terms "gastroesophageal reflux AND asthma AND children" in the PubMed tool Clinical Queries, selecting "therapy" and "broad, sensitive search." | ( Calvani, M; Radzik, D; Sopo, SM, 2009) |
| "The presence of gastroesophageal reflux, which was documented by pH monitoring in 40% of participants with minimal or no symptoms, did not identify a subgroup of patients that benefited from treatment with proton-pump inhibitors." | ( Anthonisen, NR; Castro, M; Holbrook, JT; Leone, FT; Mastronarde, JG; Teague, WG; Wise, RA, 2009) |
| "The number of gastroesophageal reflux symptoms recorded over 24 hours was lower on therapy (median 22 vs 12, P < ." | ( Bondarov, P; Davidson, G; Fjellman, M; Haslam, R; Lundborg, P; Omari, T; Sandström, M, 2009) |
| "Patients with GERD who have EE have higher reported symptom resolution rates than those with nonerosive reflux disease (NERD) when treated with proton pump inhibitors (PPIs)." | ( Monyak, JT; Orlando, RC; Silberg, DG, 2009) |
| "Gastroesophageal reflux disease (GERD) is a chronic condition that usually requires long-term maintenance therapy with proton-pump inhibitors (PPIs)." | ( Archimandritis, A; Karamanolis, DG; Sgouros, SN; Stefanidis, G; Vasiliadis, KV; Viazis, N; Vlachogiannakos, J, 2010) |
| "Gastroesophageal reflux disease (GERD)-associated changes in esophageal histology have been reported mainly after short-term medical antireflux therapy, and few individual lesions have been examined." | ( Attwood, S; Ell, C; Engström, C; Fiocca, R; Galmiche, JP; Hatlebakk, J; Junghard, O; Lind, T; Lundell, L; Mastracci, L, 2010) |
| "Alginate-based gastroesophageal reflux disease treatments have been used extensively and fall into two main categories." | ( Bakhtyari, A; Dettmar, PW; Hampson, FC; Johnstone, LM; Jolliffe, IG; Sykes, J; Taylor, G, 2010) |
| "Aggressive treatment of GERD in patients with OSAS may be helpful in the overall treatment of this select patient population." | ( Giddens, CL; Houck, JR; Orr, WC; Robert, JJ; Tawk, MM, 2009) |
| "Primary care patients with a history of GERD and long-term treatment were randomized to daily placebo with pantoprazole rescue (n = 141) or daily pantoprazole with placebo rescue (n = 62) upon relief after 4 weeks pantoprazole 20 mg." | ( de Wit, NJ; Grobbee, DE; Numans, ME; Quartero, AO; van der Velden, AW, 2010) |
| "Gastro-esophageal reflux disease (GERD) is a chronic condition, with 50-80% of patients experiencing recurrence within one year following completion of initial treatment." | ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010) |
| "Forty percentage of GERD patients recurred within 6 months following the completion of 8 week therapy with lansoprazole." | ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010) |
| "2 patients suffered from mild gastrooesophageal reflux which was treated conservatively." | ( Kanellos, D; Köckerling, F; Moesta, KT; Schug-Pass, C, 2011) |
| "Infants ages 1 through 11 months with GERD symptoms after 2 weeks of conservative treatment received open-label (OL) pantoprazole 1." | ( Comer, GM; Hinz, M; Kierkus, J; Kum-Nji, P; Li, H; Maguire, MK; Mahomedy, SH; Winter, H, 2010) |
| "Na alginate treatment for gastroesophageal reflux disease in preterm infants seems to be safe and effective." | ( Arsan, S; Atasay, B; Erdeve, O; Türmen, T, 2010) |
| "Surgical management for gastroesophageal reflux disease (GERD) is indicated for reflux uncontrolled on medical therapy." | ( Chander, J; Kar, P; Kumar, R; Lal, P; Leekha, N; Ramteke, VK, 2010) |
| "Following esomeprazole treatment, GERD symptoms were significantly improved from baseline to final visit (P ≤ 0." | ( Barker, PN; Gilger, MA; Illueca, M; Tolia, V, 2010) |
| "Pediatric patients with gastroesophageal reflux disease and certain chronic comorbidities appear to have the greatest need of maintenance PPI treatment after healing of reflux esophagitis." | ( Henderson, C; Illueca, M; Lundborg, P; Wernersson, B, 2010) |
| "Esophageal pH-metry is recommended for GERD patients with hiatus hernia or with persistent reflux symptoms after PPI therapy." | ( Chen, MH; Hu, PJ; Lin, JK; Peng, S; Wang, AJ; Xiao, YL; Xiong, LS, 2010) |
| "Consecutive symptomatic GERD patients who had positive esophageal pH studies and complete symptom resolution with initial treatment of esomeprazole were given step-down on-demand esomeprazole for 26 weeks." | ( Chan, FK; Chow, DK; Lai, LH; Sung, JJ; Wong, GL; Wu, JC, 2011) |
| "Gastroesophageal reflux and related symptoms rarely deteriorate to require additional treatment after GP in patients with NI." | ( Fukuzawa, M; Kawahara, H; Kubota, A; Mitani, Y; Nakai, H; Nose, K; Yoneda, A, 2010) |
| "In patients with concomitant GERD and OA or RA who require anti-inflammatory treatment, significantly more patients treated with celecoxib were persistent with their treatment than were patients treated with nsNSAIDs." | ( Assaf, AR; Cryer, B; Luo, X; Mardekian, J; Sands, G, 2011) |
| "Was performed an assessment of GERD symptom severity, the establishment of periodontal status of patients and analysis of the effects of GERD therapy on the course parodontopaty inflammatory genesis (chronic catarrhal gingivitis and chronic periodontitis mild)." | ( Dzhamaldinova, TD, 2010) |
| "Reflux disease, including gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR), is an extremely common condition that is diagnosed and treated routinely in an otolaryngology practice." | ( Altman, KW; Prufer, N; Vaezi, MF, 2011) |
| "WAR events are common in children with gastroesophageal reflux and difficult-to-treat RS and often associated with RLRTI." | ( Ghezzi, M; Guida, E; Jasonni, V; Mattioli, G; Pistorio, A; Rossi, GA; Sacco, O; Silvestri, M, 2011) |
| "Management of patients with gastro-oesophageal reflux disease (GORD) can be assisted by information predicting the likely response to proton pump inhibitor (PPI) treatment." | ( Heading, RC; Mönnikes, H; Schmitt, H; Tholen, A, 2011) |
| "Nonwhite patients with GERD had less severe baseline erosive oesophagitis, but were less likely than white patients to have erosive oesophagitis healing after 8-week PPI therapy." | ( Illueca, M; Johnson, DA; Monyak, JT; Sharma, P, 2011) |
| "Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD and RE) were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks." | ( Chiba, T; Fujiwara, Y; Furuta, T; Hongo, M; Ishihara, S; Kinoshita, Y; Koike, T; Kusano, M; Shimatani, T; Sugimoto, M, 2011) |
| "A total of 80 patients with GERD were double-blindedly randomized into 2 groups: 40 patients received sequential therapy with pantoprazole 40 mg injection, twice daily for 2 weeks, and then pantoprazole 40 mg oral administration,twice daily for 2 weeks; the other 40 patients received pantoprazole 40 mg oral administration alone,twice daily for 4 weeks." | ( Guo, Q; Jia, Y; Shen, S; Wang, F; Yang, Y, 2011) |
| "One hundred and four patients with GERD symptoms remaining after 4-week treatment with RPZ (10 mg/day) were randomly assigned to 4 weeks of either combination therapy [rikkunshito (7." | ( Arakawa, T; Fujimoto, K; Fujiwara, Y; Higuchi, K; Iwakiri, R; Kusano, M; Shimoyama, Y; Tanaka, M; Tominaga, K; Umegaki, E, 2012) |
| "Pharmacotherapy for gastroesophageal reflux (GER) in neonates, aimed at interfering with this physiologic process and potentially reducing the negative sequelae that providers often attribute to GER, consists primarily of drugs that increase the viscosity of feeds, reduce stomach acidity, or improve gut motility." | ( Cotten, CM; Malcolm, WF, 2012) |
| "To assess sustainability of GERD healing and whether known beneficial effects of proton pump inhibitor treatment on GERD also extend to symptoms suggestive of FD and IBS." | ( Lühmann, R; Mönnikes, H; Sander, P; Schwan, T; Straszak, A; Theek, C; van Rensburg, C, 2012) |
| "Rates of patients suffering from GERD, FD or IBS were assessed at baseline, and at last visits of treatment and observational phase." | ( Lühmann, R; Mönnikes, H; Sander, P; Schwan, T; Straszak, A; Theek, C; van Rensburg, C, 2012) |
| "In patients with GERD symptoms partially responsive to PPI therapy, lesogaberan was only marginally superior to placebo in achieving an improvement in symptoms." | ( Björck, K; Denison, H; Karlsson, M; Shaheen, NJ; Silberg, DG, 2013) |
| "Although most patients with gastro-oesophageal reflux disease (GERD) benefit from proton pump inhibitor (PPI) therapy, some experience only partial symptom relief." | ( Bytzer, P; Mattsson, H; van Zanten, SV; Wernersson, B, 2012) |
| "Proton pump inhibitors effectively treat gastroesophageal reflux disease, erosive esophagitis, duodenal ulcers, and pathologic hypersecretory conditions." | ( Ament, PW; Dicola, DB; James, ME, 2012) |
| "10 infants suspected of having GERD (gastroesophageal reflux) received oral lansoprazole therapy by tube administration." | ( Ong, KK; Rogers, IM; Samuel, KF; Singh, A; Tham, SY, 2012) |
| "Approximately 20-30% of patients with gastroesophageal reflux disease (GERD) do not experience complete symptom resolution during proton pump inhibitor (PPI) therapy." | ( Björck, K; Denison, H; Shaheen, NJ; Silberg, DG, 2013) |
| "A total of 661 patients with persistent GERD symptoms who had received a minimum of 4 weeks of PPI therapy were included in the study." | ( Björck, K; Denison, H; Shaheen, NJ; Silberg, DG, 2013) |
| "In patients with GERD symptoms partially responsive to PPI therapy, mild-to-moderate severity esophageal mucosal breaks are common (prevalence 20-30%), and may contribute to symptom etiology." | ( Björck, K; Denison, H; Shaheen, NJ; Silberg, DG, 2013) |
| "24 patients with documented GERD received esomeprazole treatment." | ( Kandulski, A; Malfertheiner, P; Mönkemüller, K; Neumann, H; Peitz, U; Weigt, J, 2013) |
| "Up to 40% of patients with gastroesophageal reflux disease fail to respond to proton pump inhibitor therapy." | ( He, XX; Hong, JB; Lv, NH; Wang, AJ; Wang, H; Xu, L; You, Y; Zhu, X, 2013) |
| "Infants diagnosed with GERD are more likely to have recurrent ALTE; treatment with antireflux medications may reduce this risk." | ( Baren, JM; Donda, K; Mittal, MK, 2013) |
| "A PASS strategy identifies GERD patients with sleep disturbance in primary care that will benefit from a change in acid-suppressive therapy." | ( Armstrong, D; Bukoski, M; Hunt, R; Lei, Y; Moayyedi, P; White, R, 2013) |
| "Extraesophageal and esophageal reflux symptoms and treatment-related side effects were assessed in 60 patients while they were on no effective antireflux medication (three-week washout period), after three month of treatment with double-dose esomeprazole, and 3 months after laparoscopic Nissen fundoplication." | ( Kellokumpu, I; Kiljander, T; Oksala, N; Ranta, A; Rantanen, T; Salminen, P, 2013) |
| "Both extraesophageal and esophageal reflux symptoms decreased after treatment with esomeprazole and were further reduced after fundoplication." | ( Kellokumpu, I; Kiljander, T; Oksala, N; Ranta, A; Rantanen, T; Salminen, P, 2013) |
| "Both extraesophageal and esophageal reflux symptoms decreased after treatment with esomeprazole and were reduced further after fundoplication." | ( Kellokumpu, I; Kiljander, T; Oksala, N; Ranta, A; Rantanen, T; Salminen, P, 2013) |
| "Additionally, patients completed a gastroesophageal reflux disease (GERD) symptoms questionnaire before and after therapy and severity score was calculated." | ( Agrawal, K; Dutta, SK; Fleisher, AS; Girotra, M; Mah'moud, MA; Motevalli, M; Nair, PP, 2012) |
| "Patients (n = 460) with symptomatic GERD experiencing troublesome symptoms on once-daily PPI therapy were enrolled in this phase II, randomised, multicentre, double-blind, placebo-controlled, dose-ranging study." | ( Cundy, KC; Huff, FJ; Vakil, NB, 2013) |
| "Signs and symptoms of GERD traditionally attributed to acidic reflux in neonates were not significantly altered by esomeprazole treatment." | ( Barker, P; Davidson, G; Illueca, M; Lundborg, P; Omari, T; Thomson, M; Wenzl, TG, 2013) |
| "Thirteen patients with GERD were treated with the proton pump inhibitor rabeprazole (RPZ; 10 mg/day), for 12 weeks." | ( Chayama, K; Eguchi, Y; Fujii, H; Fujimoto, K; Hyogo, H; Imajo, K; Itoh, Y; Kanemasa, K; Nakajima, A; Ono, M; Saibara, T; Sumida, Y; Taketani, H; Tanaka, S; Yoneda, M; Yoshikawa, T, 2014) |
| "In a multicenter survey, 433 GERD patients receiving once-daily PPI treatment completed a self-report questionnaire that included the Frequency Scale for the Symptoms of GERD (FSSG) and questions about sleep disturbances." | ( Arakawa, T; Ashida, K; Fujiwara, Y; Habu, Y; Higuchi, K; Kusano, M, 2013) |
| "About half of the GERD patients receiving once-daily standard-dose PPI treatment had refractory GERD symptoms." | ( Arakawa, T; Ashida, K; Fujiwara, Y; Habu, Y; Higuchi, K; Kusano, M, 2013) |
| "Approximately 20% have gastro-oesophageal reflux disease and this can be effectively treated with proton pump inhibitor therapy." | ( Ford, AC; Moayyedi, P, 2013) |
| "Before and after treatment, the Gerd Q scoring of uniform staining groups and shallow staining and/or non-staining groups all had a significant difference (p < 0." | ( He, YX; Li, CQ; Li, YQ; Liu, J; Song, XH; Xue, L; Yang, T; Zhang, D; Zhang, HY; Zhao, H, 2013) |
| "Gastroesophageal reflux disease is a highly frequent disorder classically characterized by the presence of heartburn and/or acid regurgitation that improves with drug therapy that reduces acid content in the stomach." | ( Serra Pueyo, J, 2014) |
| "In the subgroups of patients with GERD + DM 1 and GERD + DM 2, received treatment with IG complaints on heartburn, regurgitation, odynophagia relieved significantly earlier then in the subgroups treated with DP." | ( Fedorchenko, IuL, 2013) |
| "Patients with symptoms suspected of GERD were administered the GerdQ and underwent endoscopy (measurement of intercellular space in the biopsy specimen sampling at 2 cm above the Z-line) and 24-h impedance pH monitoring, together with a 2-week experimental treatment with esomeprazole." | ( Cui, RL; Ding, SG; Lin, L; Lin, SR; Lu, JJ; Wang, Y; Xue, Y; Zhang, HJ; Zhou, LY, 2014) |
| "Given that gastroesophageal reflux disease (GERD) is the most common cause of NCCP, initial treatment with proton-pump inhibitors (PPI) has been proposed for all patients (PPI testing), reserving esophageal function testing solely for non-responders." | ( Aliaga, V; Domenech, G; Huamán, JW; Saperas, E; Videla, S, 2014) |
| "Gastroesophageal reflux disease is the primary cause of OA, usually managed with acid suppression therapy." | ( Baxter, JN; Davies, C; Griffiths, AP; Haboubi, HN; Jenkins, GJ; McAdam, E; Spencer-Harty, S, 2015) |
| "The model of gastroesophageal reflux disease by administration of 0." | ( Limantsev, AV; Lychkova, AÉ; Pankrashin, VS; Puzikov, AM; Vasil'ev, IuV, 2013) |
| "METHODS Two hundred eighty-nine GERD patients with emotional disorders were divided randomly into two groups: group 1 received esomeprazole only (monotherapy) and group 2 received esomeprazole and flupentixol/melitracen (combination therapy)." | ( Cao, Y; Chang, H; Fan, LL; Fang, DC; Lan, CH; Wu, ZL; Yu, YY, 2014) |
| "Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes." | ( Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M, 2015) |
| "Sixty patients with GERD were divided into equal groups according to performed therapy: standard drug treatment or its combination with psychotherapeutic methods." | ( Bitkova, EN; Dicheva, DT; Iurenev, GL; Maev, IV; Sirota, NA, 2014) |
| "Control of chronic gastro-oesophageal reflux disease may be achieved either by anti-reflux surgery (ARS) or by long-term medical therapy with proton pump inhibitors (PPIs)." | ( Attwood, SE; Eklund, S; Ell, C; Fiocca, R; Galmiche, JP; Hasselgren, B; Hatlebakk, JG; Jahreskog, M; Långström, G; Lind, T; Lundell, L, 2015) |
| "We modeled GERD by treatment with pH 4." | ( Binkley, J; Gargus, M; Niu, C; Rubin, DC; Shaker, A; Vallone, JG, 2015) |
| "Participants with GERD symptoms completed the Quality of Life in Reflux and Dyspepsia, Japanese version (QOLRAD-J) questionnaire and were assigned to receive 4-week esomeprazole treatment (20 mg/day)." | ( Fueki, T; Fujimoto, S; Fujimoto, Y; Harada, K; Haruna, Y; Hatta, H; Ihoriya, C; Itano, S; Kadoya, H; Kashihara, N; Komai, N; Kuwabara, A; Mori, M; Namikoshi, T; Nishizaki, T; Obata, T; Oshiro, Y; Sasaki, T; Tokura, T; Yorimitsu, D, 2016) |
| "The frequency and severity of GERD-related symptoms were significantly reduced during the active treatment period." | ( Gilger, MA; Illueca, M; Tolia, V; Traxler, B; Vandenplas, Y; Youssef, NN, 2015) |
| "Following esomeprazole treatment, GERD symptoms were significantly improved from baseline to final visit (P ≤ 0." | ( Barker, PN; Gilger, MA; Illueca, M; Tolia, V, 2015) |
| "A total of 40 patients with GERD treated at the Peking Union Medical College Hospital between September 2004 and July 2006 were randomized to receive DBT and rabeprazole proton pump inhibitor (PPI) or rabeprazole alone." | ( Fang, X; Ke, M; Liu, X; Shang, W; Sun, X; Wang, Z, 2016) |
| "The treatment of gastro-esophageal reflux disease (GERD) shows several issues among paediatric patients." | ( Adami, R; Aquino, RP; De Cicco, F; Del Gaudio, P; Giovagnoli, S; Ricci, M; Sansone, F, 2015) |
| "The prevalence of gastroesophageal reflux disease (GERD) has been increasing worldwide, with proton pump inhibitor (PPI) administration the current mainstay therapy for affected individuals." | ( Aimi, M; Ishihara, S; Ishimura, N; Kinoshita, Y; Mikami, H; Mori, M; Oshima, N; Shimura, S; Uno, G, 2015) |
| "The frequency and severity of GERD-related symptoms were significantly reduced during the active treatment period." | ( Gilger, MA; Illueca, M; Tolia, V; Traxler, B; Vandenplas, Y; Youssef, NN, 2015) |
| "Following esomeprazole treatment, GERD symptoms were significantly improved from baseline to final visit (P ≤ 0." | ( Barker, PN; Gilger, MA; Illueca, M; Tolia, V, 2015) |
| "For the treatment of gastro-oesophageal reflux disease, S-omeprazole was significantly but marginally superior to the racemate (OR', 1." | ( Asghar, W; Jamali, F; Pittman, E, 2015) |
| "As gastro-esophageal reflux disease was thought to be the causes of the treatment-refractory apnea, therapy with gaviscon and domperidon was begun for both cases." | ( Bilgin, H; Eren, A; Kara, S, 2015) |
| "Pharmacological therapy for gastro-esophageal reflux disease has not definitively been shown to be effective in improving symptoms and hence, should be reserved especially for infants with treatment refractory apnea episodes suspected as being gastro-esophageal reflux in premature infants." | ( Bilgin, H; Eren, A; Kara, S, 2015) |
| "BACKGROUND Refractory gastroesophageal reflux disease (GERD) may deteriorate patient quality of life (QOL) despite proton pump inhibitor (PPI) therapy." | ( Akazawa, Y; Hashiguchi, K; Ichikawa, T; Isomoto, H; Matsushima, K; Minami, H; Nakao, K; Ohnita, K; Onitsuka, Y; Shiozawa, K; Takeshima, F; Tanigawa, K; Taura, N; Yamaguchi, N, 2015) |
| "Obese and overweight patients develop GERD in the presence of leptin resistance and biliary tract disease, which determines the specific features of the disease (alkaline or mixed refluxate) and the need for individualized therapy." | ( Kiselev, IE; Krolevets, TS; Lapteva, IV; Livzan, MA, 2016) |
| "The Frequency Scale for the Symptoms of Gastroesophageal reflux was administered to assess symptoms of acid-reflux and dysmotility." | ( Birring, SS; Inoue, H; Ito, I; Iwata, T; Izuhara, Y; Kanemitsu, Y; Matsumoto, H; Mishima, M; Nagasaki, T; Niimi, A; Oguma, T; Petrova, G; Tajiri, T, 2016) |
| "In up to 30% of patients with typical GERD symptoms (heartburn and/or regurgitation), acid-suppressive therapy does not provide clinical benefit." | ( Ang, D; De Santis, A; Pauwels, A; Scarpellini, E; Tack, J; Vanuytsel, T, 2016) |
| "Sixty participants with symptoms of gastroesophageal reflux disease, who have previously undergone standard treatment, will be recruited from August 2015 at Kyung Hee University Korean Medicine Hospital." | ( Han, G; Lee, H; Lee, J; Leem, J, 2016) |
| "Patients with symptoms of GERD and a diagnosis of grade A reflux esophagitis (according to the Los Angeles classification) were randomized to receive lafutidine (10 mg, twice daily) or lansoprazole (30 mg, once daily) for an initial 8 wk, followed by maintenance treatment comprising half-doses of the assigned drug for 24 wk." | ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "In patients with gastroesophageal reflux disease (GERD) and erosive esophagitis, treatment with proton pump inhibitors (PPIs) is highly effective." | ( Falk, GW; French, B; Leiman, DA; Lewis, JD; Metz, DC; Morgan, S; Riff, BP; Umscheid, CA, 2017) |
| "Gastroesophageal reflux disease (GERD) therapy is challenging and suppression of acid secretion or prokinetics do not cure all cases." | ( Băncilă, I; Dobru, D; Drug, V; Dumitrascu, DL; Frățilă, O; Goldiș, A; Grad, SM; Mureșan, C; Nedelcu, L; Porr, PJ; Sporea, I; Surdea-Blaga, T, 2016) |
| "Long-term medical therapy for GERD should be tailored to each patient to provide symptomatic control and maintain esophageal mucosal healing." | ( Kroch, DA; Madanick, RD, 2017) |
| "In patients with gastroesophageal reflux disease (GERD) and erosive esophagitis, treatment with proton pump inhibitors (PPIs) is highly effective." | ( Falk, GW; French, B; Leiman, DA; Lewis, JD; Metz, DC; Morgan, S; Riff, BP; Umscheid, CA, 2017) |
| "Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate." | ( Bonella, F; Costabel, U; Kirchgässler, KU; Kolb, M; Koschel, D; Kreuter, M; Maher, TM; Renzoni, E; Spagnolo, P; Weycker, D; Wuyts, W, 2017) |
| "Approximately 20-40% of patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) treatment." | ( Fujiwara, Y; Hasegawa, T; Inoue, A; Ishizu, H; Iwakura, N; Nakahara, K; Okuyama, M; Oyama, M; Satoh, H, 2017) |
| "We enrolled 277 GERD patients receiving continuous PPI therapy." | ( Fujiwara, Y; Hasegawa, T; Inoue, A; Ishizu, H; Iwakura, N; Nakahara, K; Okuyama, M; Oyama, M; Satoh, H, 2017) |
| "Gastroesophageal reflux disease is a common disorder in humans and has been treated for the last 67 years using fundoplication." | ( Friedrichs, N; Stelzner, F, 2017) |
| "Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy." | ( Berendsen, MA; Hillman, L; Pandolfino, JE; Thuluvath, AJ; Yadlapati, R, 2017) |
| "We assessed the relationship between gastroesophageal reflux disease (GERD) and hypertension and whether antiacid therapy could be used to control blood pressure (BP) on hypertension in patients with GERD." | ( Han, XW; Ji, F; Li, ZT; Wang, L; Wang, ZG; Yue, YQ, 2018) |
| "Patients fulfilling the GERD criteria received 14-day therapy with omeprazole (20 mg twice a day), and the effect on BP was studied." | ( Han, XW; Ji, F; Li, ZT; Wang, L; Wang, ZG; Yue, YQ, 2018) |
| "Consecutive patients with GERD adequately controlled with esomeprazole 40 mg daily, entered a 2-week lead-in period during which esomeprazole was administered 30 min before breakfast." | ( Boltin, D; Dickman, R; Gingold-Belfer, R; Kayless, H; Niv, Y; Raskin, M; Schmilovitz-Weiss, H; Zvidi, I, 2018) |
| "One hundred fifty-two patients with GERD, aged ≥21 years with moderate-to-severe regurgitation despite 8 weeks of once-daily PPI therapy, were prospectively enrolled at 21 U." | ( Abbas, G; Bell, R; Buckley, FP; Dunst, C; Gould, J; Hill, M; Jacobsen, G; Katz, P; Khaitan, L; Kothari, S; Lipham, J; Lister, D; Louie, B; Luketich, J; McDowell-Jacobs, L; Park, A; Reardon, P; Richards, W; Smith, C; Smith, CD; Williams, V; Woods, K, 2019) |
| "Patients with GERD with moderate-to-severe regurgitation, especially despite once-daily PPI treatment, should be considered for minimally invasive treatment with MSA rather than increased PPI therapy." | ( Abbas, G; Bell, R; Buckley, FP; Dunst, C; Gould, J; Hill, M; Jacobsen, G; Katz, P; Khaitan, L; Kothari, S; Lipham, J; Lister, D; Louie, B; Luketich, J; McDowell-Jacobs, L; Park, A; Reardon, P; Richards, W; Smith, C; Smith, CD; Williams, V; Woods, K, 2019) |
| "The real size of the gastro-oesophageal reflux disease (GERD) population not responding to proton pump inhibitor (PPI) therapy has still not been fully elucidated." | ( Cicala, M; Efthymakis, K; Mauro, A; Neri, M; Penagini, R; Petitti, T; Ribolsi, M; Savarino, V; Zentilin, P, 2018) |
| "Ninety patients with GERD were randomly assigned to the 1) control group (CG), who received an oral administration of omeprazole (20 mg) once per day and given WCYT placebo (3." | ( Chou, JW; Feng, CL; Hsieh, CL; Lai, HC; Li, TC; Shih, YS; Tsai, CH; Wang, KT; Yu, CJ, 2019) |
| "is as follows; Patients: who have GERD, Intervention: melatonin or melatonin receptor agonist treatment, Comparison: patients without melatonin or melatonin receptor agonist treatment, Outcome: clinical indices (or crude number or proportion of improvement) for the evaluation of symptomatic improvement which enable comparison of efficacy between patients with melatonin or melatonin receptor agonist and the control group." | ( Baik, GH; Bang, CS; Yang, YJ, 2019) |
| "Long-term maintenance treatment of gastroesophageal reflux disease (GERD) is important to prevent relapse." | ( Deguchi, H; Igarashi, A; Miwa, H; Tango, T; Teng, L; Uda, A, 2019) |
| "The efficacy of vonoprazan in GERD maintenance treatment may be higher than that of some PPIs." | ( Deguchi, H; Igarashi, A; Miwa, H; Tango, T; Teng, L; Uda, A, 2019) |
| "Morbid obesity is a key risk factor for gastroesophageal reflux; the aim of this study is to describe the technique of modified laparoscopic Rossetti fundoplication to treat morbid obesity related to GERD." | ( Cesana, G; Ciccarese, F; David, G; De Carli, S; Giorgi, R; Olmi, S; Uccelli, M, 2019) |
| "Since the treatment of gastroesophageal reflux disease (GERD) symptoms in children is of the utmost importance, the current study is aimed to evaluating the efficacy of quince syrup and ranitidine in the management of pediatric patients with symptomatic GERD." | ( Bijani, A; Gorji, N; Kamalinejad, M; Kianifar, H; Memariani, Z; Naeimi, M; Saghebi, R, 2019) |
| "Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabeprazole, followed by a switch to vonoprazan)." | ( Deguchi, H; Higuchi, K; Igarashi, A; Takeuchi, T; Uda, A; Yokoya, Y, 2019) |
| "Gastroesophageal reflux disease is commonly associated with sleeve resections and warrants postoperative acid reducing therapy." | ( Chau, WY; Dobruskin, L; Sharma, N, 2019) |
| "The observation (no gastroesophageal reflux) group had a better outcome of stenosis than those treated with omeprazole (odds ratio, 3." | ( Bianchi, ET; Bibas, BJ; Guerreiro Cardoso, PF; Minamoto, H; Pego-Fernandes, PM; Salati, M, 2019) |
| "Gastroesophageal reflux disease seems to be a negative factor for treatment response and recurrence." | ( Debie, G; Horoi, M; Kampouridis, S; Lechien, JR; Mahillon, V; Muls, V; Rodriguez, A; Saussez, S; Thill, MP, 2021) |
| "PPI-partial response GERD was defined as less than 50% improvement in the VAS for severity of symptom as well as acid reflux score by FSSG after treatment." | ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2020) |
| "Gastroesophageal reflux disease (GERD) is a common disorder, and is typically treated with proton-pump inhibitors (PPIs) as the recommended first-line therapy." | ( Cheng, Y; Dai, Y; Jiang, H; Kou, F; Li, J; Li, X; Liu, J; Lu, Q; Tan, X; Xie, C, 2021) |
| "All patients diagnosed with GERD were asked to self-report a questionnaire of frequency scale for the symptoms of GERD (FSSG) and rate their degree of satisfaction with the treatment of GERD during outpatient visit." | ( Gotoh, Y; Honda, S; Ishibashi, E; Kagawa, K; Murakami, K; Nakaya, T; Noguchi, C, 2020) |
| "Using rebamipide in the treatment of gastroesophageal reflux disease is justified because this drug has a unique mechanism of action, which eliminating the main stages of pathogenesis of the disease." | ( Gonik, MI; Ivashkin, VT; Trukhmanov, AS, 2020) |
| "We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs." | ( Kapitza, C; Meier, JJ; Menge, BA; Nauck, MA; Quast, DR; Schenker, N, 2020) |
| "Gastroesophageal reflux disease (GERD) is a common disorder, and empirical proton pump inhibitor (PPI) treatment is often the first step of management; however, up to 40% of patients remain symptomatic despite PPI treatment." | ( Talley, NJ; Zand Irani, M, 2021) |
| "Gastroesophageal reflux disease (GERD) is a common medical condition, frequently refractory to medical therapy." | ( Correa, R; Fang, W; Gayam, S; Ghareeb, E; Hagen, R; Mitchell, M; Yousaf, A; Zinn, Z, 2021) |
| "Treatment of GERD in children with CF seems not to have a stronger effect than a placebo on the severity of cough and abdominal pain." | ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| "Many patients had been diagnosed with GERD, allergic rhinitis, and asthma but had a persistent cough despite treatment of these conditions." | ( Birring, SS; Martin Nguyen, A; McGarvey, LP; Morice, AH; Muccino, DR; Schelfhout, J; Sher, MR; Smith, JA; Wu, WC; Xu, ZJ, 2021) |
| "Patients with GERD were randomized into two groups; one received omeprazole for 6 months and the control group was not treated." | ( Benhassine, F; Laid, Y; Nafissa Benhalla, K; Smati, L; Yagoubi, A, 2022) |
| "To treat symptoms of gastroesophageal reflux disease, omeprazole was replaced with famotidine, and the visual hallucinations did not recur after the omeprazole had been discontinued." | ( Kim, GS; Nunez, T; Vargas, E, 2021) |
| "The 3-year mean cumulative GERD-related and hospitalization costs per patient were ¥142,620 and ¥122,444 in PPI-first and P-CAB-first treatment groups, and ¥105,263 and ¥121,958 in EPZ-first and P-CAB-first treatment groups, respectively." | ( Eda, M; Kato, T; Miwa, H; Shiotani, A; Takeda, M; Yajima, T, 2023) |
| "For patients with gastro-oesophageal reflux symptoms, the preferred treatment is proton pump inhibitor (PPI) administration for approximately 8 weeks." | ( Li, Q; Li, Y; Liu, W; Lu, NH; Xiao, Q; Xie, Y; Xu, T; Yang, N; Zhang, H; Zheng, L; Zhou, X; Zuo, K, 2022) |
| "Combination therapy for GERD is preferred in patients with EE." | ( Bakulina, NV; Ilchishina, TA; Tikhonov, SV; Topalova, YG; Vasiliev, RV, 2022) |
| "In the treatment of non-erosive GERD, the use of dexrabeprazole at 10 mg/day is as effective as esomeprazole 20 mg/day, with the advantage that the dose is lower with an appropriate safety profile." | ( Abdo-Francis, JM; Cabrera-Álvarez, G; Martínez-Torres, H; Remes-Troche, JM, 2022) |
| "Updated AGA GERD guidelines exclude a portion of patients who historically would have been diagnosed with and surgically treated for GERD." | ( Amundson, JR; Che, S; Hedberg, HM; Ishii, S; Joseph, S; Kuchta, K; Ujiki, MB; VanDruff, VN; Zimmermann, CJ; Zukancic, H, 2023) |
| "Gastroesophageal reflux disease (GERD) is a chronic condition associated with several risk factors, but little is known about the association between hormone therapy (HT) and GERD in postmenopausal women." | ( Aldhaleei, WA; Bhagavathula, AS; DeVault, KR; Faubion, SS; Wallace, MB, 2023) |
| "Secondary outcomes included GERD-related quality of life, reflux-free days and nights, and participant-reported treatment success." | ( Bredenoord, AJ; Kuipers, T; Oude Nijhuis, RAB; Schuitenmaker, JM, 2023) |
| "Symptom assessments using GerdQ and reflux monitoring were performed before and after a 28-day treatment with 5 mg lemborexant at bedtime." | ( Hoshikawa, Y; Iwakiri, K; Kawami, N; Momma, E, 2023) |